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Abstract
Background: Little is known about the causes of childhood cancer, partly as not many children develop cancer,
although childhood cancer is a leading cause of death by disease in the young. The young age of the children
suggests that risk factors for childhood cancer may be present during pregnancy. Previous studies have shown that
exposure to trans-fat, a type of unsaturated fat common in industrially produced foods (iTFA), has adverse health
effects in adults, including the risk of developing cancer. Haematopoietic neoplasms are the most common cancer
types among European children under the age of 15 years. This study will bring new knowledge as to whether
trans-fat and other fatty acids may also increase the risk of developing haematopoietic neoplasms during
childhood.
Methods: We will investigate if the Danish iTFA legislation ban, which radically reduced the use of iTFA in
foodstuffs, influenced the risk of childhood haematopoietic neoplasms in children born either before or after the
change in legislation, adjusting for relevant secular trends. Further, in a case-control study, we will examine if levels
of fatty acids in dried blood spots from newborns can predict the risk of developing childhood haematopoietic
neoplasms. Permission from the Danish Data Protection Agency and the Ethical Committee has been granted.
Discussion: The results from this study will provide important information about fatty acids in the mother’s diet as
a contributor to development of haematopoietic neoplasms during childhood, which may result in relevant
preventive action.
Trial registration: Not relevant.
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Background
Although childhood cancer is relatively rare, it is a lead-
ing cause of death by disease in children under the age
of 15 years in Western populations [1], and the inci-
dence is rising [2]. Among the 12 major groups of child-
hood cancer, leukemia has the highest incidence, with
age standardized rate of 49 per million in the age 0–
14 years in Northern Europe [3].
The etiology of malignant tumors in the young is
mostly unknown. A small proportion of childhood can-
cers seems inherited [4] or has a viral origin [5, 6]. A
few environmental risk factors, such as high-dose radi-
ation and some chemicals are currently recognized as
causes of a small proportion of childhood neoplasms [6].
The role of diet in relation to childhood cancers has only
sparsely been investigated [7], despite increasing evi-
dence pointing towards diet as a main modifiable risk
factor for cancers among adults [8]. Chromosomal trans-
locations noticed in blood samples at birth of children
subsequently diagnosed with leukemia, suggest that initi-
ating molecular events in childhood cancer development
occur as early as in utero [9]. This emphasizes the need
to investigate exposure to potential risk factors already
during fetal development. It has been shown that during
‘critical time windows’ of fetal development fetuses are
especially vulnerable to environmental exposures. This
suggests that lack off, or excess of specific nutritional el-
ements (maternal diet) may program permanent changes
in the genome directly by oxidative DNA damage or by
epigenetic mechanisms (such as DNA methylation), and
in this way modulate later disease risk [10–12].
Trans-fats are a type of unsaturated fatty acids and
can be classified as naturally/ruminant (rTFAs) occur-
ring or industrially produced (iTFAs). Industrially pro-
duced trans-fats are formed when fats and oils are
hydrogenated by industrial processing techniques. The
proportions of iTFAs in food are generally much higher
than those of rTFAs and in most European countries
they are the main dietary source of trans-fats. Examples
of foods commonly high in iTFA are baked goods (e.g.
pies, biscuits, pastries, sweet rolls) in which shortenings
such as margarine are used, and fried foods (e.g. French
fries, chicken nuggets), while the counterpart rTFA nat-
urally occurs in low levels in diary and meat products.
Evidence of adverse health effects of iTFAs has been
increasing over the past three decades, however rTFA
seems to have a less potent effect on cardio metabolic
outcomes [13, 14]. The WHO stated that intake of
trans-fats should be as low as possible (<1% of total en-
ergy intake). Yet intake remains high in most countries
worldwide [15–17]. An example of an iTFA high diet
could be; one doughnut (3.2 g iTFA), one large portion
French fries (6.8 g iTFA) and a bag of microwave pop-
corn (10 g iTFA), corresponding to overall 23 g iTFA.
Guidance to minimize trans-fat intake is based predom-
inantly on evidence that trans-fat consumption signifi-
cantly increases the risk of coronary heart disease
(CHD), where an increase of 2% in total energy derived
from iTFA is shown to be associated with an increased
risk of death from CHD or myocardial infarction of 23%
[14]. In addition, trans-fat intake seems associated with
the development of other non-communicable diseases
like central adiposity, diabetes, Alzheimer’s disease,
endometriosis, cholelithiasis and total mortality [18].
Furthermore, among adults, iTFAs is found to be dir-
ectly associated with cancer of stomach, multiple mye-
loma, lung (in never smoking men), mouth/pharynx,
breast cancer [19, 20], non-aggressive prostate cancer
[21, 22] and colorectal cancer [23].
A case-control study investigating dietary fat and pro-
tein intake showed increased risk of non-Hodgkin
lymphoma among adults with a diet high in iTFA [24].
TFA has pro-inflammatory properties which might be
the mechanism explaining carcinogenesis. A randomized
controlled trial in women showed that industrially pro-
duced iTFA induced low-grade systemic inflammation
by elevating circulating concentrations of tumor necrosis
factor (TNF) α and its receptors [25]. TFA exposure in
mice during pregnancy and lactation has shown to affect
the global DNA methylation in the dams, thus TFA in-
take may exert long-term effects on the epigenome fol-
lowing maternal exposure [26].
Studies demonstrating relationships between trans-fat
intake and cancer in childhood are lacking. However,
evidence has shown some possible negative effects on
other health outcomes among children. Bouwstra and
colleagues have shown that neonates with high TFA um-
bilical levels have a less favorable neurologic condition
at 18 months [27]. Furthermore, a recent review (includ-
ing human and animal studies) concluded that fetal ex-
posure to trans-fat appears to increase the offspring risk
for developing metabolic diseases throughout life [28].
TFAs also interfere in the metabolism of long-chain
polyunsaturated fatty acids which might result in a nega-
tive impact on infant growth and development [29, 30].
Lifelong, including prenatal, consumption of a diet rich
in polyunsaturated fatty acids (PUFA, contained in nuts,
seeds and fish) has been shown to protect against tumor
growth and to modify glucose metabolism in Walker
tumor cells and lymphocytes in Wistar rats [31]. There-
fore, the inhibitory effect of PUFA and their interference
with trans fatty acids might also be relevant in the fetal
programming of childhood cancers.
Despite a general reduction in the iTFA use in food
production, Denmark, as the first EU country, legislated
against the use of iTFA in all Danish and imported hu-
man foodstuffs [32]. The order came into effect on
March 31st, 2003, with a transition period until January
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1st, 2004. The order imposed a maximum of 2 g of
iTFA/100 g oils and fats. During the transition period a
maximum level of 5% iTFA was allowed in foodstuffs
also containing ingredients other than oils and fats [32].
This legislation led to a radical reduction of iTFA from
margarine and shortenings which resulted in a rapid de-
cline in products with trans-fat followed by a decrease in
population-level CVD mortality rates [33].
Despite the alarming evidence of increased risk of sev-
eral diseases caused by TFA consumption and the fact
that millions of people still have a too high iTFA intake
in Europe, currently no EU legislation regulates the con-
tent of iTFA in food products [34].
Given the direct associations found between high TFA
intakes and some cancer types among adults, and the
deleterious health effects associated with higher TFA in-
takes among the fetus and offspring, other detrimental
effects of an early life exposure to trans-fats, such as
childhood cancer, could be envisaged. The health effects
of TFA during gestation have never previously been
followed in large populations, in part because large-scale
interventions are needed to examine how TFA exposure
during pregnancy affects long-term health outcomes of
offspring, and in particular the risk of developing child-
hood cancer. However, such interventions may never be
conducted due to the associated high financial and logis-
tical costs and ethical aspects. Therefore, alternative
study designs should be used to explore associations be-
tween early life trans-fat exposure and childhood
cancers.
Hypotheses and objectives
We hypothesize that high TFA exposures, and in par-
ticular iTFA exposures, during the critical phase of fetal
development increase the risk of developing childhood
cancers in general and haematopoietic neoplasms in
particular.
We investigate this in two broad designs and study
objectives:
1) We will examine if the legislatively reduced use of
iTFA in the production of human foodstuff for the
Danish market has shown any beneficial effect on
population level in preventing childhood
haematopoietic neoplasms. Thus we will compare
the incidence of childhood haematopoietic
neoplasms between all Danish children born in the
years before and after the law came into effect. The
specific hypothesis is that individuals born in 2004–
2008 were exposed to reduced iTFA during fetal
development and will have a lower risk of
developing childhood haematopoietic neoplasms
compared to individuals born in 1988–2003, before
the policy was implemented, while taking into
account the underlying secular trends in these
cancers.
2) We aim to compare neonatal levels of TFA in
children with and without a later diagnosis of
childhood haematopoietic neoplasm in a matched
case-control study. As a secondary aim, we wish to
investigate the interactions between TFA and poly-
unsaturated fatty acids, and their impact on risk of
haematopoietic neoplasms in children, since TFA
have been shown to inhibit the metabolism of poly-
unsaturated fatty acids.
The aim of this protocol is to describe the methods
and analyses that will be used in this study to investigate
the influence of prenatal exposure to trans-fatty acids
for development of haematopoietic neoplasms (En-
Trance). If deviations from this initial study protocol
occur during data analyses, we will update the protocol.
Methods
As childhood cancers are histologically and etiologically
very diverse, investigating effects of prenatal TFA intake
on each type of the childhood cancer would require very
large sample sizes given the low incidence rates of differ-
ent tumour types. Therefore, we restrict our study to in-
vestigating the potential adverse effects of a high TFA
exposure on risk of haematopoietic neoplasms (ICD-10
codes: DC81-C96), the most frequent cancer types in
children.
The two objectives of this study reinforce each other
by first investigating effects of the trans-fat order on
fetal programming of haematopoietic neoplasms on
population level and second by investigating variations
in biomarkers of TFA and risk of haematopoietic neo-
plasms, based on measurements of individual exposures.
Therefore, null findings in the first objective would not
necessarily imply null findings in the second objective.
Study population
The cancer registry is complete until December 31st
2015. To secure equal time of follow-up for cancer diag-
nosis in all individuals we censor at 7 years of age, which
is the longest follow-up time in which we have informa-
tion on possible cancer outcomes for all individuals.
We will exclude all children born with a Down’s Syn-
drome (DS) diagnoses due to their increased risk of
childhood leukemia [35] and due to secular trends in DS
incidence, because of a new screening practice for DS
and other chromosomal aberrations introduced in 2004.
In the first objective, national birth cohorts of individ-
uals born between January 1st, 1988 and December 31st,
2008 in Denmark will be included (Fig. 1). This is a
register based study using the Danish civil registration
number which will be linked to the Danish National
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Cancer Register, where the cancer patients are followed-
up until December 31st, 2015.
The incidence of childhood haematopoietic neoplasms
among 1,101,055 individuals from the period before the
iTFA legislation born between January 1st, 1988 and Au-
gust 31st, 2004, will be compared to the incidence of
childhood haematopoietic neoplasms among 276,422 in-
dividuals from the period after the iTFA legislations
born between September 1st, 2004 and December 31st,
2008, as a proxy of iTFA gestationally exposed or not ex-
posed, respecitvely. In this overall time period approxi-
mately 740 incident haematopoietic neoplasms cases
occurred in children before the age of 7 years.
The second objective is a case-control study investigat-
ing biomarkers of neonatal trans-fatty acid concentra-
tions from stored DBS [34] from individuals who
developed childhood haematopoietic neoplasms before
the age of 7 years and born in the period 1988–2008
compared to matched controls (Fig. 2).
Since 1981, routinely collected DBS samples taken by heel
prick 48–72 h after birth have been collected for all new-
born in Denmark. DBS cards are stored in the Biological
Specimen Bank for Neonatal Screening at Statens Serum
Institute and have been made available to the project [36].
For each case with haematopoietic neoplasms, a con-
trol, individually matched for gender, exact date and year
of birth, mother’s parity, place of birth, being alive and
with no diagnosis of cancer, will be selected and fatty
acids isomers measured in the DBS. A case is defined as
a child, less than 7 years, with a cancer diagnosis (ICD-
10 DC81-C96) and without a DS diagnosis [37]. If more
than one participant meets the matching criteria a ran-
dom control from the eligible participants will be se-
lected. If no participant meets the matching criteria the
1st of January 1988 1st of September 2004 31st of December 2008
Trans-fat legislation 1st 
of January 2004 
Trans-fat exposed cases 
Trans-fat non-exposed cases
Fig. 1 Constitution of the exposed versus non-exposed groups of cases who developed haematological malignancy before the age of 7 years
and registered in The Danish Cancer Registry (Objective 1)
All children born in 1981 -2017 with dried blood spots (DBS) in
the Danish Neonatal Screening Biobank, close to 100% of 
children born in Denmark, Greenland and the Faroe Islands
All children with a diagnosis 
coded to ICD 10 C81-C96 
before age 7 years, born in 
the period 1988-2008 
Cases with 
insufficient DBS 
quality or quality, 
expecting 20%
700 controls matching the cases
by date of birth, gender, 
mother’s parity, place of birth, 
being alive and with no 
diagnosis of any cancer700 cancer cases
Children born 
prior to 1988 or 
after 2008 , and
children born in 
Greenland or the 
Faroe Islands
Fig. 2 Flow chart of the matched case-control study (Objective 2)
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criteria for exact date of birth or place of birth will be
relaxed as needed to match controls to cases and the ad-
justments made will be reported.
Previous studies have confirmed that storage time of
DBS as long as 20 years do not bias inter-individual vari-
ation in concentrations of vitamin D and possible other
fat soluble substances [38]. Furthermore, as date of birth
is used as matching criterion for the controls, potential
degradation of TFA would affect equally cases and con-
trols and is therefore unlikely to bias the results.
The methodology for measuring biomarkers of fatty
acids in DBS has been set up at the International Agency
of Research of Cancer (IARC) in Lyon, France, a special-
ized WHO and UN organization. The DBS will securely
be transported from Denmark to IARC, Lyon, France,
where they will be kept in a − 80 °C freezer until analysis.
Our validated gas chromatography methodology allows
a complete separation, identification and quantification
of sixty fatty acids from short-chain saturated to long-
chain polyunsaturated fatty acids, including fifteen indi-
vidual isomers of industrial trans fatty acids (elaidic acid,
trans n-6 and n-3 PUFA) separated from natural trans
fatty acids (CLA, vaccenic acid) in one-hour runs. The
laboratory involved in the set up at IARC is at the cut-
ting edge of lipidomic technologies and have developed
sound and innovative high-throughput methods for fatty
acid measurements [20]. Fatty acid concentrations will
be determined in plasma phospholipids, as some specific
fatty acids measured in this lipid fraction have been
shown to be reliable biomarkers of specific dietary in-
takes, as well as fatty acid metabolism [39–41]. Samples
from cases and their matched controls will be analysed
within the same daily batch, with two quality controls in
each batch. The technical staff will not have any infor-
mation on the case/control status. Total lipids will be
extracted from plasma samples with chloroform-
methanol containing antioxidant butylated hydroxytolu-
ene and L-A-phosphatidylcholine-dimyristoyl-d as an
internal standard. Phospholipids will be purified by ad-
sorption chromatography; fatty acid methyl esters will be
separated through gas chromatography. The relative
amount of each fatty acid, expressed as percent of total
fatty acids, will be quantified by integrating the area
under the peak and dividing the result by the total area.
Fatty acids will also be expressed as absolute concentra-
tions in plasma (μmol/l) based on the quantity of the
methyl deuterated internal standard.
Based on this methodology, coefficients of variation
(CVs) for fatty acids have been calculated for 60 samples.
CVs ranged from 0.013% for large peaks to 7.75% for the
smallest peaks (less than 0.10% of total fatty acids).
Overall CVs (within-batch and between batch CVs) are
very good for iTFA isomers, mainly for elaidic acid (CV
= 0.137%). Overall CV is 0.122% for total iTFA. CVs for
rTFAs are also good, mainly for vaccenic acid, the main
iTFA isomer (CV = 0.282%). CV for total iTFA is 0.123%.
Because the TFA levels in the new-born blood also re-
flects the TFA status of the mother at the end of preg-
nancy, measurement of iTFA levels in DBS will
furthermore serve as validation for the effect of trans-fat
elimination for incident cases.
To take into account different cohort effects or
changes in life-style in the period 1988 to 2008, we will
merge the cohort data with information from the Danish
Medical Birth Registry on trends in co-variates which
might have changed during the time period, e.g. smoking
during pregnancy and age of the mother.
Power calculation
Using the command stpower for the log-rank test for
comparison of two survival functions in Stata 14 we
calculated the least detectable hazard ratio (exposed
versus unexposed) to be 1.35 assuming 80% power
and a significance level of 5% in objective 1 (the
cohort study) [42].
In objective 2 (the case-control study) we have a sam-
ple size of 700 cancer cases and 700 controls, and as-
suming 80% power, the least detectable OR will be
between 1.35 and 1.75, depending on the exposure
among the controls (10–90%). The power analysis for
the matched 1:1 case-control study was performed using
the power mcc command in Stata 14 [43].
Statistical analysis
In objective 1 we will use a Cox proportional hazard
model with age as the underlying timescale to investigate
the hazard of childhood haematopoietic neoplasms in
children born before and after the iTFA ban, as a proxy
for iTFA exposed or not exposed in fetal life. Observa-
tions will be censored in case of death, immigration or
at 7 years of age. To take the potential secular trend in
the incidence of haematopoietic neoplasms into account
we will model the variation in cancer risk across birth
cohorts by a piecewise linear spline with a knot at 1st of
September 2004. Further, we will investigate incidence
trends over time.
By examining all children from the entire national
birth cohorts it is reasonable to assume that all con-
founding variables will be equally distributed among the
exposed and non-exposed individuals, but still we will
investigate potential influence of secular variation or
possible confounding effects which might have changed
during the time period and which might be associated
with both TFA exposure and haematopoietic neoplasms.
Such potential confounders could be age of the mother
at the time of giving birth, assuming accumulation of
TFA with age and an older age for first time pregnancies
over time. The median gestational age might have
Specht et al. Nutrition Journal  (2018) 17:13 Page 5 of 8
increased during the investigated time period, which
would increase the average intrauterine exposure to TFA
over the study period [44]. Smoking status during preg-
nancy might have decreased over time and smoking
might be associated with increased cancer risk, smoking
is also associated with gestational age and thereby with
the length of the TFA exposure during pregnancy.
As sub-analysis we will exclude cancer cases diagnosed
before the 90 day of life since the origin most likely is
due to chromosomal alterations leading to oncogene ac-
tivation [37]. If feasible we will investigate the first born
only since some studies have shown higher risk of child-
hood cancers in the first born compared to their youn-
ger siblings [45] and sensitivity analysis of sub-types of
haematopoietic neoplasms (leukemia and lymphoma).
Further, we will investigate children with early diagnosis,
e.g. before age 4 years.
Conditional logistic regression analyses will be used in
the 2nd objective to compare blood spot fatty acid levels
between subjects with haematopoietic neoplasms and
matched subjects who have not developed cancer. We
will investigate industrial as well as ruminant TFA inde-
pendently and mutually adjusted. Based on a priori con-
sideration we will adjust for maternal and paternal age,
smoking during pregnancy, birth weight and gestational
age. Also, there might be regional and urban/rural differ-
ences in iTFA intake. Place of residence is available from
Statistics Denmark, and can be included into analyses.
Diets are usually different between families with higher
and lower socioeconomic status and maternal socioeco-
nomic status may influence intake of certain food prod-
ucts rich in trans-fat. Information on socioeconomic
status, education and ethnicity is available from Statistics
Denmark and can be controlled for.
As mentioned in the methods description, other fatty
acids potentially related to haematopoietic neoplasms in
children will be analysed in the DBS since our method-
ology allows a complete separation, identification and
quantification of sixty fatty acids. We will therefore also
investigate interactions between TFA and polyunsatur-
ated fatty acids, and risk of haematopoietic neoplasms in
children as well as association between polyunsaturated
fatty acids and risk of cancer stratified by trans fatty
acids.
Discussion
Our main goal for this study is to strengthen the scien-
tific basis for understanding idiopathic haematopoietic
neoplasms in children. By presenting the protocol before
undertaking the actual analyses, we intend to improve
the quality, integrity and transparency of the study.
Strengths of the first objective include the unselected
national cohort, the prospective design and the register-
based measure of outcome. This explorative study takes
advantage of the iTFA elimination policy implemented
in Denmark almost fifteen years ago, and nests this “so-
cietal experiment” in a setting where the effect of condi-
tions from conception (and before) for development of
certain diseases can be followed among individuals from
birth and onwards. The study is possible due to
complete identification of every resident in Denmark via
a civil registration number. This number can be linked,
on an individual level, to Danish birth, patient and med-
ical registries; social and ethnic registries; and clinical
and other national databases. The comprehensive link-
age of datasets for both aims makes it possible to study
mediation, confounding and/or modification of effects of
iTFA for childhood haematopoietic neoplasms.
For the first objective we do not collect any individual
data on iTFA intake. In contrast, all individuals are unse-
lected in relation to iTFA exposure and later disease oc-
currence. This may be considered a very strong feature
of the present study, as neither confounding from exter-
nal or internal factors, nor the lack of individual data on
iTFA intake, is a prerequisite for the study, as the influ-
ences of lifestyle differences (e.g. use of infant formula,
individual diet intake, use of supplements), or biological
(adipose tissue stores, weight changes during pregnancy
and post-partum) which we would not be able to adjust
for, are all independent of the iTFA legislation.
Nevertheless, the proposed study design, especially in
the first objective, also implies some uncertainties, in-
cluding a potential ecological fallacy. The exposure
measure is applied equally to all members of the cohort
before and after the ban, while the individual exposures
have probably differed. However, a previous study has
shown a marked decline of average iTFA intake resulting
in elimination after the ban [32]. In the case-control
study we investigate TFA exposure individually in all
cases from 1988 to 2008. The variations in the exposure
observed in the case-control study will then inform our
assumptions taken in the cohort study.
Any societal changes preceding 1988 or succeeding
2008 will influence the exposed and control groups simi-
larly, while results will be confounded by any potential
societal changes occurring around the time where the
trans-fat ban was implemented (e.g. 2003/04). However,
we are unaware of such changes except for a screening
for DS which we have taken into account by excluding
children with DS.
Potentially exposure to TFA from maternal adipose
stores could affect the “unexposed” group (born after
the ban of iTFA) and postnatal influences like maternal
feeding practice and weight gain, may also influence can-
cer risk through a non-TFA mechanism. Although this
may indeed seem a possible limitation, since literature
has shown that weight loss of the mother (e.g. during
lactation) liberates TFA fat deposits [44], proper
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randomization in our societal experiment study is mim-
icked by separating exposed and non-exposed individ-
uals by one point in time with a minimum of selection
bias. Thus, it is an obvious strength to the present re-
search design, that the individuals will be unselected,
and generally representative of the Danish population, in
relation to exposed vs. non-exposed to the trans-fat le-
gislation, as well as to the development of haematopoi-
etic neoplasms. However, since we do not know the
exact mechanism between TFA and childhood neo-
plasms, we cannot account for a residual confounding
which might affect observed associations. Residual con-
founding could be caused by additional components in
food products with high contents of TFA. We are not
able to investigate TFA levels at specific developmental
stages during gestation, but since no knowledge exist on
specific target windows for childhood cancers, this may
not be relevant.
Other health outcomes in children, which will not be
described in this protocol, will be investigated in future
studies using the same study designs, include: negative
birth outcomes, cognitive function, epilepsy, asthma,
heart disease, eye diseases, bone fracture, and metabolic
diseases like type 1 diabetes and childhood obesity.
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